Alterity Therapeutics Limited (PRNAF PINK) stock market data APIs
$0.0029
0(0%)
as of July 10, 2025
Try our APIs with
free plan!
Alterity Therapeutics Limited Financial Data Overview
Price chart is built with
Anychart
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
Prev. Close
0.0029
Open
0.0029
High
0.0029
Low
0.0029
52 wk Range
0.0029-0.0139
Market Cap
52 242 K
Shares Outstanding
8 882 M
Revenue
3 724 K
EPS
-0.0012
Beta
0.72
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Alterity Therapeutics Limited data using free add-ons & libraries
Get Alterity Therapeutics Limited Fundamental Data
Alterity Therapeutics Limited Fundamental data includes:
- Net Revenue: 3 724 K
- EBITDA: -20 493 620
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-04-29
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Alterity Therapeutics Limited News
New
Life Sciences Investor Forum Presentations Now Available for On-Demand Viewing
Virtual Investor Conferences NEW YORK, June 24, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from ...
UPDATE - Life Sciences Investor Forum: Company Executives Present Live June 23rd
Virtual Investor Conferences Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com NEW YORK, June 21, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the...
Life Sciences Investor Forum: Company Executives Present Live June 23rd
Virtual Investor Conferences Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com NEW YORK, June 21, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the...
Dr David Stamler Appointed CEO
MELBOURNE, Australia, Jan. 7, 2021 /PRNewswire/ -- The Board of Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") is pleased to announce the appointment of Dr David Stamler ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
